Introduction

Delhi NCR (National Capital Region) has rapidly emerged as a growing biotech hub in India, blending homegrown innovation with global collaboration. The biotech companies in Delhi NCR range from pioneering vaccine manufacturers to cutting-edge startups in genomics and healthcare. The region benefits from proximity to top research institutions (AIIMS, ICGEB, etc.) and support from government initiatives like the Biotechnology Industry Research Assistance Council (BIRAC) headquartered in New Delhi. In recent years, India's biotech sector has seen robust growth – the country's "bioeconomy" crossed an estimated $80 billion in value by 2021, reflecting increasing output in biopharma, diagnostics, and bio-services.

Delhi NCR contributes significantly to this boom with its mix of established firms and agile startups. Notably, many of these companies leverage modern R&D infrastructure and digital platforms to accelerate research and ensure data integrity. The following profiles spotlight 10 leading biotech players in the Delhi NCR region, followed by an outlook on how this ecosystem is shaping the future of biotech in India.

‍

‍

Top 10 Biotech Companies in Delhi NCR

Panacea Biotec (New Delhi)

Panacea Biotec is one of India's oldest and most respected biotech-pharma companies, headquartered in New Delhi. Founded in 1984, Panacea Biotec made its mark by developing affordable vaccines and pharmaceutical formulations for global markets. The company has a broad portfolio spanning vaccines (polio, hepatitis, etc.), biosimilars, and novel drug formulations. It was a key supplier of polio vaccines in India's immunization programs and has invested heavily in R&D for new vaccines. Panacea's focus on innovation is evident from its work on vaccine candidates for dengue and universal influenza, and on biologic therapies for diabetes and oncology. It operates multiple R&D and manufacturing facilities, ensuring end-to-end product development. As a pioneer in vaccine development with principal offices in Delhi, Panacea Biotec exemplifies the region's strength in combining scientific research with large-scale manufacturing. The company's integrated approach to affordable healthcare solutions has allowed it to reach over 85 countries, making New Delhi a node in the global vaccine and biotech supply chain.

Jubilant Pharmova (Noida, Uttar Pradesh)

Jubilant Pharmova (part of the Jubilant Life Sciences group) is a major biopharmaceutical company based in Noida (NCR). The company evolved from a family business into a diversified life sciences giant, and it now serves three key markets: novel therapeutics, contract research, and pharmaceuticals. Under the leadership of Shyam S. Bhartia, Jubilant has established R&D centers in Noida and Bengaluru, focusing on oncology and autoimmune disorder drugs. The company is also a world leader in radiopharmaceuticals (diagnostic and therapeutic radioactive products) which are exported globally. Notably, Jubilant Pharmova's contract research arm collaborates with biotech innovators worldwide, reflecting NCR's role as a bridge between Indian expertise and international biotech development. With thousands of employees and a presence in over 100 countries, Jubilant's success underscores how Delhi NCR hosts enterprises that excel in both innovation and large-scale production. The company's continual investment in R&D and manufacturing infrastructure in the region has solidified its status as one of India's top integrated biotech-pharma firms.

Mankind Pharma (New Delhi)

Mankind Pharma is a pharmaceutical powerhouse that began in New Delhi in 1995 and rose to become one of India's top five pharma companies. While known primarily for its extensive range of affordable generic medicines and consumer healthcare products (from antibiotics to pregnancy tests), Mankind has in recent years ventured into biotech-driven areas like biosimilars and novel therapeutics. The company has an R&D center in Manesar (Gurugram) and has invested in developing products for chronic diseases such as diabetes and cardiovascular conditions. Mankind's rapid ascent – now boasting over 20,000 employees and a multi-billion dollar revenue – reflects a focus on high-volume, affordable healthcare solutions. It has introduced important products to the Indian market, like an insulin glargine biosimilar for diabetes in partnership with overseas firms, expanding treatment options for patients. In 2023, Mankind Pharma's successful IPO was one of the country's largest, underlining investor confidence in its growth strategy and pipeline. From a small Delhi startup in the mid-90s to a leading pharma-biotech conglomerate, Mankind's journey illustrates the supportive environment that Delhi NCR offers for scaling healthcare innovations. The company continues to explore new biologics and vaccine partnerships, signaling a future where it could blend its manufacturing might with cutting-edge biotech R&D.

Lifecare Innovations (Gurugram)

Lifecare Innovations is a Gurugram-based biotech company renowned for its specialization in novel drug delivery systems. Founded by Dr. Jitendra Nath Verma and Dr. Lilly Verma in the late 1990s, this niche firm gained fame as the first in India to develop and manufacture liposomal Amphotericin B – an advanced formulation of a critical antifungal drug. Marketed as Fungisome, their liposomal amphotericin B was introduced about two decades ago and was lauded as one of India's top pharmaceutical innovations of the 2000s. This formulation offered a more affordable, locally made alternative to imported therapies for severe fungal infections like mucormycosis (the "black fungus"). In 2021, during a surge of black fungus cases post-COVID, Lifecare Innovations worked round the clock to ramp up Fungisome production, highlighting the company's critical role in India's healthcare response. Beyond antifungals, Lifecare has developed liposomal and nano-formulations for diseases such as kala-azar and cancer, focusing on improving efficacy and reducing side effects. As a smaller enterprise, Lifecare Innovations exemplifies the high-impact biotech research happening in NCR: it translates laboratory advances into life-saving products. Its success has also paved the way for greater acceptance of indigenous biotech solutions in Indian healthcare, demonstrating the region's capability in advanced drug delivery R&D.

‍

‍

MedGenome Labs (Gurugram/Bangalore)

MedGenome is India's leading genomics and clinical diagnostics company, with a significant presence in Delhi NCR through its state-of-the-art Gurugram lab. Founded in 2013 and headquartered in Bangalore, MedGenome operates the largest CAP-accredited genetic testing lab in South Asia. The company offers over 1,300 genetic tests covering oncology, cardiology, neurology, rare diseases, and reproductive health, making advanced genomics accessible to physicians and patients across India. MedGenome has been a pioneer in affordable high-throughput DNA sequencing and bioinformatics analysis, contributing to both clinical care and research. During the COVID-19 pandemic, MedGenome partnered with India's government and global agencies to provide widespread COVID-19 testing and to sequence coronavirus variants, leveraging its massive genomics capacity. The company attracted investments from international players like IFC (World Bank Group), underlining its status as a leading genetic diagnostics and research company. MedGenome's expansion into Gurugram was aimed at increasing access to genetic tests in North India and tapping the region's medical community. From early cancer detection panels to population genomics projects, MedGenome's work is at the forefront of India's precision medicine wave. Its use of genomic data from Indian populations is generating insights into disease genetics, placing NCR on the global map for genomics research. As data-centric biotech grows, many labs in the region (including MedGenome) rely on robust digital infrastructure for handling the terabytes of genomic data these companies generate, ensuring seamless data integration and compliance.

Premas Biotech (Gurugram)

Premas Biotech is an innovative biotech startup based in Gurugram (Manesar) known for its work in vaccine development and difficult-to-express proteins. Founded in 2005 by a team of scientists led by Dr. Prabuddha Kundu, Premas built a reputation as a contract research organization specializing in recombinant protein expression. More recently, Premas made international headlines during the COVID-19 pandemic by developing a unique triple-antigen virus-like particle (VLP) vaccine candidate against SARS-CoV-2. This vaccine design targets three different viral proteins (Spike, Membrane, and Envelope), aiming to broaden protection against current and future variants. Premas formed a joint venture, Oravax Medical Inc., with US-based Oramed Pharmaceuticals to develop an oral COVID-19 vaccine using Premas's VLP technology combined with Oramed's oral delivery platform. In 2021, Oravax and Premas announced licensing deals to bring this vaccine technology to the Indian market, illustrating global confidence in Premas's innovation. Beyond vaccines, Premas's platform (called D-Crypt™) has been used for R&D in therapeutic proteins and antibodies. The company's ability to solve complex R&D challenges for partners worldwide has turned it into a go-to collaborator for biotech projects, despite its modest size. Premas Biotech's success highlights the NCR region's capacity for cutting-edge biotech R&D – the company operates at a quality standard comparable to global biotech hubs, while benefiting from India's talent and cost advantages. As Premas scales up manufacturing for its vaccine and other biologics, the support of lab digitization tools could further streamline its R&D workflows and regulatory compliance, accelerating its path to market.

PredOmix (Gurugram)

PredOmix is a health-tech biotech startup based in Gurugram, known for its breakthrough in cancer diagnostics. The company, co-founded by Dr. Kanury Rao in 2018, developed OncoVeryx, a novel blood test that uses metabolomics and artificial intelligence to detect multiple cancers at early stages. In 2022, PredOmix launched OncoVeryx-F, a test capable of simultaneously screening for four female-specific cancers (breast, cervical, ovarian, and endometrial) from a single blood sample. By 2023, they expanded the technology to detect about 32 types of cancer in both men and women with exceptionally high accuracy (~98%). This patented approach identifies unique metabolite signatures of cancers using AI algorithms, addressing a huge unmet need in oncology screening. According to news reports, the PredOmix test can even pinpoint the tissue of origin of a cancer, which is crucial for follow-up care. The startup's innovation drew significant attention as it could revolutionize early cancer detection in India, where routine screening for many cancers is lacking. PredOmix has conducted large-scale validation studies with thousands of samples and has filed international patents. The success of PredOmix exemplifies the new wave of biotech startups in Delhi NCR that combine life sciences with AI. With growing clinical adoption, the company is poised to save lives by catching cancers earlier than ever before. Startups like PredOmix also showcase how the NCR region fosters interdisciplinary innovation – blending biochemistry, data science, and clinical research – to create globally relevant healthcare solutions.

Advancells (Noida)

Advancells is a Noida-based biotech company at the forefront of regenerative medicine, specializing in stem cell therapies. Founded in 2013 by Vipul Jain, Advancells began with the vision of harnessing the "untapped and unmatched potential" of stem cells to treat degenerative diseases. The company has since grown into a leading provider of stem cell-based solutions in India. Advancells focuses on isolating adult stem cells (mostly from bone marrow or adipose tissue) and providing them to partner hospitals for use in experimental therapies for conditions like neurological disorders, orthopedic injuries, and even diabetes. Uniquely, Advancells operates on a B2B model, supplying high-quality stem cell preparations to a network of around 55 hospitals and clinics in India and abroad. This approach allows specialized doctors to offer cutting-edge treatments (such as stem cell transplants for spinal cord injury or Parkinson's) under approved clinical protocols. By 2018, the company had achieved impressive growth – scaling from modest revenues to over ₹10 crore ($1.3M) in four years, and projecting 50% year-on-year growth. Advancells has also ventured into patient consulting, guiding individuals to appropriate stem-cell based clinical trials or therapies. As one of the pioneers in India's cell therapy domain, Advancells had to overcome skepticism and build awareness among medical professionals. Its success in NCR demonstrates the region's openness to futuristic biotech fields. With India preparing regulatory frameworks for stem cell and gene therapies, companies like Advancells are well-positioned. They also emphasize digital record-keeping for tracking cell lineages and patient outcomes to ensure traceability and compliance in regenerative products.

‍

‍

Clensta International (Delhi)

Clensta International is an IIT Delhi-incubated startup bringing biotech innovation to personal care and hygiene. Founded in 2016 by Puneet Gupta, Clensta developed a patented "waterless bathing" technology that enables cleaning without using water. The idea was originally to help defense personnel and patients who lack easy access to water to maintain hygiene. Clensta's flagship products – a Waterless Body Bath and Waterless Shampoo – allow a full cleanse with just an application of a quick-drying biodegradable solution, saving litres of water per use. This sustainable innovation attracted wide interest, and Clensta expanded its portfolio to more than 28 products within a few years. During the COVID-19 pandemic, the startup also launched a Covid-Guard surface disinfectant lotion with long-lasting antiviral protection. Clensta's approach exemplifies how Delhi's biotech startups apply science to solve everyday problems – in this case, combining chemistry and microbiology to formulate effective no-water cleansers. The company gained a major boost in 2021 when pharmaceutical giant Cipla partnered with Clensta to market and distribute its waterless tech products across hospitals, pharmacies, and even the Indian defense forces. This partnership not only validated Clensta's technology but also scaled it nationwide. With growing awareness about water conservation, Clensta's product line is poised for international markets as well. The startup's progress also highlights how support from institutions like IIT Delhi and grants (e.g., the Department of Science & Technology's NIDHI scheme) in NCR can catalyze biotech entrepreneurship. By merging innovation with sustainability, Clensta is carving out a unique niche in the biotech consumer products space.

Genes2Me (Gurugram)

Genes2Me is a fast-growing molecular diagnostics company based in Gurugram, focused on developing advanced genetic tests and kits. Established in 2016 by Neeraj Gupta, Genes2Me set out to make preventive genetic testing more accessible in India. Pre-pandemic, the company offered a range of services including prenatal screening, newborn genetic tests, and oncology panels using next-generation sequencing (NGS). However, Genes2Me truly came into the limelight during the COVID-19 crisis, when it became one of the major domestic suppliers of RT-PCR testing kits and rapid test kits. Gurugram-based Genes2Me offers genetic testing for preventive and diagnostic health, and has been actively supplying COVID-19 test kits across India. By rapidly scaling manufacturing, Genes2Me delivered millions of made-in-India COVID-19 diagnostic kits, helping the country reduce reliance on imports. The company developed innovative products like an extraction-free COVID PCR kit that gives results in 40 minutes, and a portable PCR machine, demonstrating its R&D agility. Genes2Me has also launched a series of NGS-based clinical panels for oncology and inherited diseases, positioning itself as a leading provider of turnkey IVD solutions (In Vitro Diagnostics). With certifications like CE-IVD and ISO13485, it has gained trust in both domestic and some overseas markets for quality. Genes2Me's story highlights NCR's strength in the diagnostics segment of biotech – leveraging a skilled workforce to produce world-class diagnostic tech quickly. The company continues to expand into point-of-care testing devices and aims to integrate AI for analyzing genetic data. As it grows, Genes2Me represents how Delhi NCR startups are contributing to healthcare self-sufficiency. The use of digital Laboratory Information Management Systems (LIMS) and data analytics is central to Genes2Me's operations, ensuring that its high-throughput labs maintain accuracy and efficiency.

‍

Future Outlook

A Thriving Biotech Ecosystem in NCR

The biotech industry in Delhi NCR is poised for robust growth in the coming years. With a strong foundation of companies across vaccines, pharmaceuticals, diagnostics, and novel therapies, the region is expected to attract increased investments and partnerships. Government support remains a key driver – for instance, the Department of Biotechnology and BIRAC are actively funding startups and fostering incubators in the area. New science parks and research centers in Faridabad and NCR are on the horizon, aiming to bring academia and industry closer. By 2030, India's overall biotech sector is forecasted to reach new heights (some estimates put the national biotech market at a ~$150 billion potential), and Delhi NCR will play a significant role in this expansion. We can anticipate more global pharma and biotech firms setting up R&D collaborations or facilities in the region, drawn by the talent pool and India's cost advantages.

Innovation, Collaboration, and Digital Transformation

A notable trend in the NCR biotech scene is increased collaboration – between large pharma and nimble startups, and between industry and research institutes. Many of the top companies profiled (such as Premas Biotech and PredOmix) have demonstrated the value of partnerships, whether it's joint ventures for vaccine development or tie-ups to bring novel diagnostics to market. This collaborative ethos is likely to deepen, with NCR serving as a meeting point for international initiatives. Moreover, there is a growing recognition of the importance of digital transformation in biotech R&D. Companies are managing vast datasets, from clinical trial data to genomic sequences, and the need for efficient lab management is paramount. By adopting modern digital tools, even relatively small startups can maintain "pharma-grade" data integrity and compliance, which is crucial for regulatory approvals and quality control. The future will likely see every lab in this ecosystem leveraging AI and software to augment their research processes, enabling teams to achieve more with less and accelerating time-to-market for new therapies.

Challenges and Opportunities Ahead

While the outlook is optimistic, Delhi NCR's biotech sector will face challenges that need addressing. Scaling up manufacturing for biologics and high-tech products requires continuous investment in infrastructure and training. As some companies transition from R&D to commercial production (e.g., a startup moving to manufacturing a vaccine or a diagnostic kit at scale), they will need support in technology transfer and regulatory navigation. Competition from established biotech clusters in Bangalore and Hyderabad means NCR must capitalize on its unique advantages – such as stronger links to policymakers, proximity to national regulators, and a concentration of hospitals for clinical research. The good news is that NCR's diverse biotech portfolio (as seen with the ten companies above) provides resilience. The region is not reliant on a single domain; it spans pharma, health-tech, agri-biotech, and more. This diversity encourages cross-pollination of ideas – a pharma company can learn digital innovation from a health-tech startup, or a diagnostics firm can partner with a genomics lab for a new test. Crucially, the next wave of growth in NCR biotech will depend on nurturing talent. With AI and machine learning becoming integral to biotech (for drug discovery, personalized medicine, etc.), we expect to see more bio-IT convergence in the region. Institutes and companies are already training a new generation of scientists who are as comfortable with coding as they are with pipetting. The presence of digital health platforms and similar SaaS providers in the biotech domain also indicates a rising demand for bioinformatics and data management skills. Ensuring a steady pipeline of such skilled professionals through universities and skilling programs will be essential.

‍

Conclusion

Delhi NCR's biotech sector stands at an exciting inflection point. The top companies highlighted here – from stalwarts like Panacea Biotec to trailblazers like PredOmix – showcase a region that can innovate, manufacture, and adapt in the face of global health challenges. The collaborative ecosystem, backed by policy support and an entrepreneurial spirit, has created a fertile ground for biotech ventures of all sizes. As these companies continue to grow, their success will feed a virtuous cycle, inspiring more startups and attracting more investment into the NCR biotech cluster. In the coming years, we can expect Delhi NCR to not only contribute significantly to India's biotech ambitions but also to make its mark internationally through novel products and partnerships. With an emphasis on innovation, sustainability, and digital empowerment, the future of biotech in Delhi NCR looks bright – driving improvements in healthcare and quality of life, and solidifying the region's status as a biotech powerhouse in the Indian subcontinent.

‍